Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
Sheng-Mou Hsiao, Chun-Hou Liao, Ho-Hsiung Lin, Hann-Chorng Kuo
Int Neurourol J. 2015;19(3):171-177.   Published online 2015 Sep 22
DOI: https://doi.org/10.5213/inj.2015.19.3.171
Citations to this article as recorded by
  Crossref logo
Evaluation of the relationship of cholinergic metabolites in urine and urgency urinary incontinence
David Sheyn, Sara Myers, Dominique Tucker, Fred E. Hazlett, Xiaolin Li, Britt Conroy, Adonis K. Hijaz
International Urogynecology Journal.2022; 33(5): 1165.     CrossRef
Overactive bladder symptoms recurrence after sudden versus gradual weaning of Solifenacin
Ahmed Abdelbary, Ahmad Aref Al-Dessoukey, Ayman Salah Moussa, Mohamed Saif El-nasr, Akrm Ahmed Elmarakbi, Ahmed Medhat Ragheb, Ahmed Mohamed Elbatanouny, Ahmed Abdellateef, Osama Sayed, Amr Lotfy, Khaled Mohyelden, Amr Mohamad Abdelhamid, Ehab Mohamad Gal
African Journal of Urology.2020;[Epub]     CrossRef
The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study
Sheng-Mou Hsiao, Ting-Chen Chang, Ho-Hsiung Lin
Maturitas.2019; 126: 11.     CrossRef
Development and Validation of a Machine Learning Algorithm for Predicting Response to Anticholinergic Medications for Overactive Bladder Syndrome
David Sheyn, Mingxuan Ju, Sixiao Zhang, Caleb Anyaeche, Adonis Hijaz, Jeffrey Mangel, Sangeeta Mahajan, Britt Conroy, Sherif El-Nashar, Soumya Ray
Obstetrics & Gynecology.2019; 134(5): 946.     CrossRef
Medical treatment of female overactive bladder syndrome and treatment-related effects
Sheng-Mou Hsiao, Ho-Hsiung Lin
Journal of the Formosan Medical Association.2018; 117(10): 871.     CrossRef
The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis
Jure Tornic, Jalesh N. Panicker
Current Neurology and Neuroscience Reports.2018;[Epub]     CrossRef
Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?
Maurizio Serati, Umberto Leone Roberti Maggiore, Paola Sorice, Simona Cantaluppi, Enrico Finazzi Agrò, Fabio Ghezzi
International Urogynecology Journal.2017; 28(7): 1033.     CrossRef
VAISTŲ, VARTOJAMŲ DIRGLIOSIOS ŠLAPIMO PŪSLĖS SINDROMO GYDYMUI, EFEKTYVUMO PALYGINIMAS
Vita Kvekšaitė, Ieva Vasilavičiūtė, Monika Zinkevičiūtė, Povilas Aniulis, Rosita Aniulienė
Sveikatos mokslai.2017; 27(3): 27.     CrossRef
Oral pharmacological therapy for urinary incontinence
Dae Kyung Kim
Journal of the Korean Medical Association.2016; 59(3): 215.     CrossRef
High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
Chun-Hou Liao, Hann-Chorng Kuo
Medicine.2016; 95(45): e4962.     CrossRef